Fig. 4

Decision curve analysis depicting net benefit derived from the training, internal and external validation sets. ((A) Training set; (B) Internal validation set; (C) External validation set 1; (D) External validation set 2. The horizontal and ordinate axis of this figure represented threshold probability, and the net benefit after the advantages were subtracted by the disadvantage, respectively. When a patient’s HSIL + risk reached a certain threshold, it was defined as high risk and biopsy measures were taken to further confirm final diagnosis. Decision curve analysis showed higher net benefit than biopsy for all patients, which suggests this model developed in this study is clinical usefulness)